Endometrial cancer first stage cure

The effectiveness of uterine cancer treatment is generally measured by the 5-year survival rate, not cure. The 5-year survival rate for stage Ia surgery or radiotherapy is 98% to 100%; stage Ib is 90% to 90%, and stage IIa is about 70%. Prognosis is very important for the 5-year survival rate.

Generally speaking, adenocarcinoma is not sensitive to radiotherapy and has a high rate of lymph node metastasis, so the prognosis is worse than that of squamous cell carcinoma. The degree of differentiation of cancer cells is related to the prognosis. The better the differentiation, the better the prognosis.

If adenocarcinoma and squamous cell carcinoma coexist, this mixed cancer is highly malignant, metastasizes early, and has a poor prognosis. Therefore, in the treatment of uterine cancer, it is necessary to strictly master the indications and contraindications of surgery, radiation, and combined surgery and radiation therapy. The surgery must be thorough and truly achieve the requirements of radical cure; the radiotherapy plan and method must be correct; auxiliary measures must be timely and appropriate, including correcting anemia, preventing and correcting nutritional deficiencies, and preventing and treating infections and complications, which are all factors that determine the prognosis.

In order to better control the disease, it is recommended to take (ginsenoside Rh2) capsules to enhance the body's immunity and resistance, maintain normal white blood cell values, promote recovery, anti-inflammatory and analgesic, prevent and treat infection, and prevent complications.